Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D059246 | Tachypnea NIH | 1.00 |
D000860 | Hypoxia NIH | 0.18 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002789 | Tachypnea HPO | 1.00 |
HP:0012418 | Hypoxemia HPO | 0.19 |
Navigate: Correlations HPO
There is one clinical trial.
The coronavirus disease 2019 (COVID-19) initially developed at the beginning of December 2019 in Whuan, Hubei province of China has spread all over the world. Beside the most common symptoms at onset of illness including fever, fatigue, dry cough, myalgia and dyspnoea, there are less common symptoms such as headache abdominal pain, diarrhoea, nausea and vomiting. The proportion of patients complaining gastrointestinal symptoms is variable between 3,4% and 17,0%. Interestingly, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) RNA has been reported to be detectable in 50% of patients' stool samples and in these patients around the 50% had diarrhoea. SARS-CoV2 transmission has been reported to be through droplets. However, mounting evidence indicates that SARS-CoV2 has a tropism for the gastrointestinal tract and is excreted with faeces. Accordingly, a faecal-oral route of transmission of the virus has been recently postulated. Indeed, SARS-CoV2 binds to host ACE 2 receptors (ACE2) to entry into cells which are abundantly expressed by intestinal epithelial cells and regulate intestinal inflammation. Taken together, this evidence could provide a rational basis for the development of gastrointestinal symptoms reported by COVID19 infected patients. Primary aim: to evaluate the prevalence and prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease Secondary aims 1. to evaluate long term consequences of COVID-19 on gastrointestinal symptoms 2. to evaluate long term consequences of COVID-19 on the development of post-infection irritable bowel syndrome (PI-IBS) 3. to evaluate long term consequences of COVID-19 on the development of post-infection dyspepsia 4. to assess the clinical and laboratory predictors (risk factors) of post-infection gastrointestinal symptom development
Description: For the primary aims of the study, the presence of gastrointestinal symptoms at admission and at follow-up made 1 month after discharge will be evaluated. In particular, the validated Gastrointestinal Symptom Rating Scale (GSRS) questionnaire (a 7-points Likert scale) will be used to assess the prevalence of gastrointestinal symptoms. The following laboratory test will be evaluated: complete blood cell count, indexes of inflammation, liver and kidney function.
Measure: Prevalence of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease as assessed by GSRS questionnaire Time: one monthDescription: For the prognosis, mortality rates (%) at one month will be evaluated.
Measure: Prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease Time: one monthDescription: to evaluate long term consequences of COVID-19 on the development of PI IBS, the validated Rome IV Diagnostic Questionnaire for Irritable Bowel syndrome will be used. This questionnaire translates the Rome IV diagnostic criteria into questions that can be understood and reported by patients, assisting the clinicians in arriving at a positive diagnosis. The prevalence (%) of new IBS diagnosis will be evaluated by this questionnaire.
Measure: Long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) irritable bowel syndrome (IBS). Time: 12 monthsDescription: to evaluate long term consequences of COVID-19 on the development of PI dyspepsia, the validated Rome IV Diagnostic Questionnaire for Dyspepsia will be used. This questionnaire translates the Rome IV diagnostic criteria into questions that can be understood and reported by patients, assisting the clinicians in arriving at a positive diagnosis. The prevalence (%) of new dyspepsia diagnosis will be evaluated by this questionnaire.
Measure: long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) dyspepsia. Time: 12 monthsDescription: Data recorded at admission and used for the primary aims of the study will be tested as predictors of post-infection gastrointestinal symptoms onset occurring within a specific time frame using the Logistic Regression or Cox regression method. Subsequently to confirm their independent predictive value, the variables with p <0.1 will be studied in a multivariate logistic or Cox model.
Measure: Identification of risk factors for post-infection gastrointestinal symptom development. Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports